These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 35485300)

  • 1. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
    Song L; Liu S; Zhao S
    Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway.
    Gao F; Li R; Wei PF; Ou L; Li M; Bai Y; Luo WJ; Fan Z
    Bioengineered; 2022 Mar; 13(3):6332-6342. PubMed ID: 35209807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Gubenyiliu formula II and its disassembled prescriptions on cell autophagy in breast cancer through PI3K/AKT/mTOR pathway.
    Chen X; Jin G; Luo H; Zhou L
    Anticancer Drugs; 2023 Jul; 34(6):725-734. PubMed ID: 36727774
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Zhou L; Xie Y; Li Y
    Front Immunol; 2022; 13():871705. PubMed ID: 35860248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
    Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
    Mardanshahi A; Gharibkandi NA; Vaseghi S; Abedi SM; Molavipordanjani S
    Mol Biol Rep; 2021 Aug; 48(8):1-14. PubMed ID: 34357550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sinomenine exerts a neuroprotective effect on PD mouse model through inhibiting PI3K/AKT/mTOR pathway to enhance autophagy.
    Bao X; He Y; Huang L; Li H; Li Q; Huang Y
    Int J Neurosci; 2024 Jun; 134(3):301-309. PubMed ID: 35815397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4
    Celada LJ; Rotsinger JE; Young A; Shaginurova G; Shelton D; Hawkins C; Drake WP
    Am J Respir Cell Mol Biol; 2017 Jan; 56(1):74-82. PubMed ID: 27564547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway.
    Pei XD; Yao HL; Shen LQ; Yang Y; Lu L; Xiao JS; Wang XY; He ZL; Jiang LH
    Eur J Pharmacol; 2020 Sep; 883():173355. PubMed ID: 32687921
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Jeong YH; Kim TI; Oh YC; Ma JY
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.
    Albert JM; Kim KW; Cao C; Lu B
    Mol Cancer Ther; 2006 May; 5(5):1183-9. PubMed ID: 16731750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
    Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
    Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
    Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
    Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy
    Choi EY; Han EJ; Jeon SJ; Lee SW; Moon JM; Jung SH; Park YS; Park BK; Kim BS; Kim SK; Jung JY
    Anticancer Res; 2024 Jul; 44(7):2961-2972. PubMed ID: 38925830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.